End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
49.06 CNY | +2.08% |
|
+10.62% | +47.55% |
Jul. 16 | Haisco Pharmaceutical Receives US FDA Approval for Autoimmune Drug Trials | MT |
Jul. 07 | Haisco Pharmaceutical to Raise 1.37 Billion Yuan via Share Placement; Shares Slump 5% | MT |
Company Valuation: Haisco Pharmaceutical Group Co., Ltd.
Data adjusted to current consolidation scope
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 18,638 | 21,747 | 23,695 | 25,545 | 36,883 | 54,420 | - | - |
Change | - | 16.68% | 8.96% | 7.81% | 44.38% | 47.55% | - | - |
Enterprise Value (EV) | 18,638 | 21,747 | 23,695 | 25,545 | 36,883 | 54,420 | 54,420 | 54,420 |
Change | - | 16.68% | 8.96% | 7.81% | 44.38% | 47.55% | 0% | 0% |
P/E ratio | 30.2x | 63.8x | 85.6x | 85.7x | 95x | 96.8x | 73.6x | 56x |
PBR | 6.46x | 7.73x | - | 6.17x | 8.84x | 11.7x | 9.71x | 9.14x |
PEG | - | -1.4x | -4.6x | 22.28x | 3.2x | 2.2x | 2.3x | 1.8x |
Capitalization / Revenue | 5.59x | 7.84x | - | 7.61x | 9.91x | 12.2x | 10.1x | 8.37x |
EV / Revenue | 0x | 0x | - | 0x | 0x | 12.2x | 10.1x | 8.37x |
EV / EBITDA | 0x | 0x | - | 0x | 0x | 67.8x | 51.4x | 38.1x |
EV / EBIT | 0x | 0x | - | 0x | 0x | 82.5x | 62.8x | 47.6x |
EV / FCF | - | - | - | - | 0x | 104x | 90x | 65.3x |
FCF Yield | - | - | - | - | 0.09% | 0.96% | 1.11% | 1.53% |
Dividend per Share 2 | - | - | - | 0.2 | 0.135 | 0.07 | 0.045 | 0.12 |
Rate of return | - | - | - | 0.86% | 0.41% | 0.14% | 0.09% | 0.24% |
EPS 2 | 0.58 | 0.32 | 0.26 | 0.27 | 0.35 | 0.5067 | 0.6667 | 0.8767 |
Distribution rate | - | - | - | 74.1% | 38.6% | 13.8% | 6.75% | 13.7% |
Net sales 1 | 3,337 | 2,773 | - | 3,355 | 3,721 | 4,446 | 5,389 | 6,500 |
EBITDA 1 | 805.9 | 691.9 | - | 529.1 | 463.3 | 802.4 | 1,058 | 1,427 |
EBIT 1 | 692.2 | 512.3 | - | 313.5 | 507.4 | 659.4 | 867.1 | 1,143 |
Net income 1 | 618.4 | 345.1 | 277 | 295.1 | 395.5 | 567.7 | 743 | 980.3 |
Net Debt | - | - | - | - | - | - | - | - |
Reference price 2 | 17.52 | 20.40 | 22.25 | 23.15 | 33.25 | 49.06 | 49.06 | 49.06 |
Nbr of stocks (in thousands) | 1,063,821 | 1,066,028 | 1,064,949 | 1,103,460 | 1,109,260 | 1,109,260 | - | - |
Announcement Date | 2/26/21 | 4/26/22 | 4/17/23 | 4/19/24 | 4/11/25 | - | - | - |
1CNY in Million2CNY
Estimates
P/E ratio, Detailed evolution
P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
---|---|---|---|---|---|---|
96.83x | - | - | 0.14% | 7.58B | ||
36.13x | 11.98x | 27.23x | 0.77% | 693B | ||
14.63x | 4.31x | 11.78x | 3.15% | 394B | ||
27.14x | 6.49x | 13.73x | 3.45% | 334B | ||
15.94x | 5.78x | 11.57x | 3.18% | 287B | ||
14.37x | 3.52x | 8.72x | 3.82% | 259B | ||
16.56x | 4.4x | 10.31x | 3.49% | 223B | ||
21.78x | 4.08x | 12x | 2.32% | 215B | ||
10.26x | 3.33x | 7.2x | 4.02% | 201B | ||
22.54x | 5.77x | 11.13x | 3.25% | 158B | ||
Average | 27.62x | 5.52x | 12.63x | 2.76% | 277.25B | |
Weighted average by Cap. | 22.69x | 6.58x | 15.11x | 2.68% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- 002653 Stock
- Valuation Haisco Pharmaceutical Group Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions